Upstream Bio, Inc. (NASDAQ:UPB) is among the best low priced stocks to get rich in 2026. On June 12, JPMorgan significantly ...

WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the appointment of three clinical advisors and new ...

Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027. Upstream Bio, Inc. announced the completion of patient enrollment in ...

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Upstream Bio, Inc.

Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...

- Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP - - Company ...

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

- Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use- -Secondary endpoints also provided strong ...

Thank you for standing by, and welcome to the Upstream Bio Phase II VIBRANT Top-line Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to ...

Upstream Bio (UPB) is scheduled to report Q2 earnings on August 5, 2026. Analysts estimate EPS of $-0.76 and quarterly revenue of $435.80K. In the most recent quarter (Q1), Upstream Bio reported EPS ...

Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated ...

– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary ...